Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 8, 2013, Pages 632-640

  Zhao, Luqian ^a   Huang, Ping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Plasminogen activator inhibitor 1; Polymorphism; Type 2 diabetes

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; ASIAN; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAI 1 4G GENE; PAI 1 5G GENE; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR;

EID: 84884271053     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dall T, Nikolov P and Hogan P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-932.
2. Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva, Switzerland: World Health Organization. 1999; 31: 1-59.
3. Zimmet P, Alberti K and Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
4. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117.
5. Auwerx J, Bouillon R, Collen D and Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arterioscler Thromb Vasc Biol 1988; 8: 68-72.
6. Festa A, Williams K, Tracy RP, Wagenknecht LE and Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-1759.
7. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-1855.
8. Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R and Arakawa M. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1. Kidney Int 1998; 54: 1659-1669.
9. [Ding GX, Shen J and Chen JW. Relationship between polymorphisms of PAI-1 gene, ATN gene and coronary heart disease in type 2-DM: report of 281 cases. Acta Nangjing Med Univ 2001; 21: 95-98.
10. Li CG, Dong XH, Wang HY, Si YG, Liu WS, Zhai MX, Wang J and Liu L. Association of plasminogen activator inhibitor type-1 4G/5G polymorphism and type 2 diabetes with nephropathy. Chin J Diabetes 2001; 9: 333-336.
11. Liu SQ, Xue YM, Yang GC, He FY, Zhao XS. Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 904-907.
12. Pan SZ, Yan XF, Lin JY and Yang LY. Association of ACE and PAI-1 gene polymorphisms with plasma PAI-1 level in type 2 diabetes patients. Chin J Endocrinol Metab 2004; 20: 451-452.
13. Wang XD, Fan Z, Fu Y, Yin H, Zhai YL, Qi YH, Zhu YQ, Wang J and Zhao XY. 4G/5G polymorphism at plasminogen activator inhibitor-1 promoter in patients with type 2 diabetes and coronary artery disease. J Capital Med University 2004; 25: 223-226.
14. Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS, Kathiresan S, Gabriel SB, Larson MG, Yang Q, Herbert AG, Wilson PW, Feng D, Tofler GH and Cupples LA. PAI-1 Gene 4G/5G Polymorphism and Risk of Type 2 Diabetes in a Populationbased Sample. Obesity 2006; 14: 753-758.
15. [Liu YH, Zhou ZG, Tan SZ, Lin J, Chen XY, Liu ZW, Ning J and Xiong B. Association of PAI-1 gene polymorphism with the femoral artery intimamedia thickness in patients with type 2 diabetes. J Chin Physic 2006; 8: 2-4.
16. Wang SY, Meng XM, Tang YX and Yu X. The relationship between PAI-1 activity and 4G/5G polymorphism in patients with type 2 diabetes from the coastal areas of Shandong province. J Chin Physic 2006; 8: 8-10.
17. Wei R, Wu GT, Yu C, Wang C, Sheng CJ and Han YQ. Association of PAI-1 levels and its promoter 4G/5G genotype with correlated factors in T2DM. Chin J Diabetes 2006; 14: 261-262.
18. Zheng TS, Liu L., Zhou WR, Li M, Xu J, Lu HJ and Xiang KS. Correlation of plasminogen activator inhibitor-1 gene polymorphism with type 2 diabetic nephropathy in Chinese. J Shanghai Jiaotong University 2007; 27: 774-776.
19. Saely CH, Muendlein A, Vonbank A, Sonderegger G, Aczel S, Rein P, Risch L and Drexel H. Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographied coronary patients. Clin Chim Acta 2008; 396: 18-22.
20. Yan XF, Pan SZ, Yan SJ and Zhang SJ. Relationship between plasminogen activator inhibitor 1 gene polymorphism and the level of endothelium-dependent vasodilatation in patients with type 2 diabetes. Clin Med Chin 2008; 24: 708-710.
21. Al-Hamodi Z, Saif-Ali R, Ismail IS, Ahmed KA and Muniandy S. Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects. Biomed Res Int 2012; 2012: 234937.
22. Thakkinstian A, McElduff P, D'Este C, Duffy D and Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005; 24: 1291-1306.
23. [Nie W, Chen J and Xiu Q. Cytotoxic T-Lymphocyte Associated Antigen 4 Polymorphisms and Asthma Risk: A Meta-Analysis. PLoS One 2012; 7: e42062.
24. Nie W, Fang Z, Li B and Xiu QY. Interleukin-10 promoter polymorphisms and asthma risk: A meta-analysis. Cytokine 2012; 60: 849-855.
25. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
26. Wang Y, Rimm EB, Stampfer MJ, Willett WC and Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555-563.
27. Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G and Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999; 19: 1361-1365.
28. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE and Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346.
29. De Taeye BM, Novitskaya T, Gleaves L, Covington JW and Vaughan DE. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 2006; 281: 32796-32805.
30. Schäfer K, Fujisawa K, Konstantinides S and Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842.
31. Crandall DL, Quinet EM, El Ayachi S, Hreha AL, Leik CE, Savio DA, Juhan-Vague I and Alessi MC. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26: 2209-2215.
32. Lijnen HR, Alessi MC, Frederix L, Collen D and Juhan-Vague I. Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost 2006; 96: 731.
33. Franco RF and Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 2001; 115: 491-506.